Taiwan Biotech Company (1789) Reports Q4 2025 Financials: EPS at NT$0.17
NQ Score
45/100
N1 Content Completeness
3
AI Summary (NQ-processed)
Taiwan Biotech Company (TWSE: 1789) announced its fourth quarter 2025 financial results, reporting basic earnings per share (EPS) of NT$0.17. The company's revenue for the quarter reached NT$3.163 billion, with a net profit after tax of NT$137 million. Taiwan Biotech operates within the biotechnology and healthcare industry, focusing on active pharmaceutical ingredients (APIs).
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What were Taiwan Biotech Company's earnings per share for Q4 2025?
- A: Taiwan Biotech Company reported basic earnings per share of NT$0.17 for the fourth quarter of 2025.
- Q: What was Taiwan Biotech Company's revenue in Q4 2025?
- A: The company's operating revenue for Q4 2025 was NT$3.163 billion.
- Q: What was Taiwan Biotech Company's net profit after tax in Q4 2025?
- A: Taiwan Biotech Company's net profit after tax for Q4 2025 was NT$137 million.
- Q: What industry does Taiwan Biotech Company operate in?
- A: Taiwan Biotech Company operates in the biotechnology and healthcare industry.